| dc.contributor.author | Feng Chen | |
| dc.contributor.author | Jiefu Yang | |
| dc.contributor.author | Yingying Li | |
| dc.contributor.author | Hua Wang | |
| dc.contributor.other | Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, National Center for Cardiovascular Diseases China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China | |
| dc.contributor.other | Department of Cardiology, Beijing Hospital, National Center of Gerontology, 100730, Beijing, China | |
| dc.contributor.other | Department of Cardiology, Beijing Hospital, National Center of Gerontology, 100730, Beijing, China | |
| dc.contributor.other | Department of Cardiology, Beijing Hospital, National Center of Gerontology, 100730, Beijing, China; Corresponding author. Department of cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China. Tel: +86 13911680467. | |
| dc.date.accessioned | 2025-10-09T05:17:54Z | |
| dc.date.available | 2025-10-09T05:17:54Z | |
| dc.date.issued | 01-07-2018 | |
| dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S1109966617304281 | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40930 | |
| dc.description.abstract | Objective: We Sought to identify circulating miRNAs suitable for HF diagnosis. Methods: In this study, a genome-wide plasma miRNA microarray was performed in 13 HF patients and 3 controls. The expression levels of selected differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were validated with quantitative real-time PCR (qRT-PCR) assays in an independent cohort of 33 HF patients and 20 controls. Results: Of all the miRNAs analyzed, miR-3135b (P<0.001), miR-3908 (P<0.001), and miR-5571-5p (P<0.001) were found to have significantly different expression levels in HF compared to controls. The Receiver operating characteristic (ROC) curves for miR-3135b, miR-3908, and miR-5571-5p revealed area under the curve (AUC) values of 1.00, 0.86, and 0.94, respectively. More importantly, miR-3135b and miR-3908 were able to discriminate heart failure with reduced ejection fraction (HFrEF) from heart failure with preserved ejection fraction (HFpEF) (P<0.05). The miR-5571-5p plasma level was significantly associated with NYHA class (P<0.001). Conclusion: This study demonstrated for the first time that some specific microRNAs (miR-3135b, miR-3908, and miR-5571-5p) are useful biomarkers for HF and for differentiating HFrEF from HFpEF. Keywords: miRNAs, heart failure, biomarkers | |
| dc.language.iso | EN | |
| dc.publisher | Elsevier | |
| dc.subject.lcc | Diseases of the circulatory (Cardiovascular) system | |
| dc.title | Circulating microRNAs as novel biomarkers for heart failure | |
| dc.type | Article | |
| dc.description.pages | 209-214 | |
| dc.description.doi | 10.1016/j.hjc.2017.10.002 | |
| dc.title.journal | Hellenic Journal of Cardiology | |
| dc.identifier.oai | oai:doaj.org/journal:1dcf9667e37b441fb9f6f407e1d82805 | |
| dc.journal.info | Volume 59, Issue 4 | |
